A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Luvadaxistat (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms ERUDITE
- Sponsors Neurocrine Biosciences
- 30 Jul 2024 Planned End Date changed from 1 Mar 2025 to 1 Jan 2025.
- 01 May 2024 According to a Neurocrine Biosciences media release, top-Line Phase 2 Data expected in Q3 2024.
- 10 Apr 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Jul 2024.